JAZZ vs KVYO · P/E 1988, rev $2.28B vs rev $1.23B
Jazz Pharmaceuticals PLC (JAZZ) versus Klaviyo, Inc. (KVYO) — a side-by-side from cached financials, not a winner call.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Klaviyo, Inc. (KVYO) is a software - infrastructure company listed on US.
Latest reported JAZZ revenue for 2026-06-30 was $2.28B. Net income was $485.9M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Latest reported KVYO revenue for 2025-12-31 was $1.23B. Net income was -$31.8M. Revenue was up 31.6% from 2024-12-31 to 2025-12-31. KVYO currently screens at market cap $9.88B.
JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1. KVYO currently screens at market cap $9.88B.
Not investment advice. Open the JAZZ and KVYO stock pages for the full models.
Not investment advice.